PSTR yields 5.12% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, PSTR + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PSTR + PFE for your $10,000?
PSTR pursues favorable returns by continuously evaluating economic, political, and market conditions to identify opportunities and mitigate potential declines. Portfolio allocation is based on forecasting methods, incorporating sector analysis and top-down macroeconomic indicators like key industry drivers, financial metrics, and return forecasts. Additionally, bottom-up fundamental analysis of individual securities is also part of the approach. While it maintains core investments in sectors represented in the S&P 500, it periodically shifts selection and weighting towards sectors across the broader domestic market. The strategy is intended to capitalize on the potential alpha arising from variations between sector allocations and the broad market. To further enhance returns and generate income, it utilizes a covered call option writing strategy. The fund may engage in active and frequent trading. Investments may include equity ETFs and derivatives.
Full PSTR Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.